General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Amendment of Notice, 61507 [2010-24983]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 192 / Tuesday, October 5, 2010 / Notices
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: September 30, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2010–24984 Filed 10–4–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
General and Plastic Surgery Devices
Panel of the Medical Devices Advisory
Committee; Amendment of Notice
AGENCY:
Food and Drug Administration,
HHS.
mstockstill on DSKH9S0YB1PROD with NOTICES
ACTION:
BILLING CODE 4160–01–S
The Food and Drug Administration
(FDA) is announcing an amendment to
the notice of meeting of the General and
Plastic Surgery Devices Panel of the
Medical Devices Advisory Committee.
This meeting was announced in the
Federal Register of August 16, 2010 (75
FR 49940). The amendment is being
made to reflect a change in the Agenda
portion of the document. There are no
other changes.
FOR FURTHER INFORMATION CONTACT:
Margaret McCabe-Janicki, Center for
Devices and Radiological Health, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, rm. 1535,
Silver Spring, MD 20993–0002, 301–
796–7029, or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area), code 3014512519. Please call the
Information Line for up-to-date
information on this meeting.
SUPPLEMENTARY INFORMATION: In the
Federal Register of August 16, 2010,
FDA announced that a meeting of the
General and Plastic Surgery Devices
Panel of the Medical Devices Advisory
Committee would be held on November
18, 2010. On page 49940, in the second
column, in the Agenda portion of the
document, the first full paragraph is
changed to read as follows:
Agenda: On November 18, 2010, the
committee will discuss, make
recommendations, and vote on
information related to the premarket
approval application for MelaFind,
sponsored by MELA Sciences.
MelaFind(R) is a non-invasive and
objective multi-spectral computer vision
system designed to aid physicians in the
detection of early melanoma from
18:36 Oct 04, 2010
Dated: September 30, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2010–24983 Filed 10–4–10; 8:45 am]
Notice.
VerDate Mar<15>2010
among clinically atypical (those having
one or more clinical or historical
characteristics of melanoma, such as
asymmetry, border irregularity, color
variegation, diameter greater than 6
millimeters, evolving, patient concern,
regression, and ‘‘ugly duckling’’)
cutaneous pigmented lesions that are
non-ulcerated, not bleeding, and less
than 2.2 centimeters in diameter, when
a physician chooses to obtain additional
information before making a final
decision to biopsy to rule out
melanoma.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to the advisory committees.
Jkt 223001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Research Centers at Minority-Serving
Institutions.
Date: October 20, 2010.
Time: 8 a.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Chang Sook Kim, PhD,
Scientific Review Officer, Review Branch,
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7190,
Bethesda, MD 20892, 301–435–0287,
carolko@mail.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
PO 00000
Frm 00097
Fmt 4703
Sfmt 4703
61507
Mentored Patient Oriented Research Career
Development Awards.
Date: October 21, 2010.
Time: 8 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 8120 Military Road, NW.,
Washington, DC 20015.
Contact Person: Stephanie J. Webb, PhD,
Scientific Review Officer, Review Branch/
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7196,
Bethesda, MD 20892, 301–435–0291,
stephanie.webb@nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Programs of Excellence in Glycosciences.
Date: October 25–26, 2010.
Time: 8 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: YingYing Li-Smerin, MD,
PhD, Scientific Review Officer, Office of
Scientific Review, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6701 Rockledge Drive, Room 7184, Bethesda,
MD 20892–7924, 301–435–0277,
lismerin@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Program Project in Cardiac Fibrillation.
Date: October 28, 2010.
Time: 10 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: William J Johnson, PhD,
Scientific Review Officer, Review Branch/
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7178,
Bethesda, MD 20892–7924, 301–435–0725,
johnsonwj@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: September 28, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–24932 Filed 10–4–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
E:\FR\FM\05OCN1.SGM
05OCN1
]]>Agencies
[Federal Register Volume 75, Number 192 (Tuesday, October 5, 2010)]
[Notices]
[Page 61507]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-24983]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0001]
General and Plastic Surgery Devices Panel of the Medical Devices
Advisory Committee; Amendment of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is announcing an amendment
to the notice of meeting of the General and Plastic Surgery Devices
Panel of the Medical Devices Advisory Committee. This meeting was
announced in the Federal Register of August 16, 2010 (75 FR 49940). The
amendment is being made to reflect a change in the Agenda portion of
the document. There are no other changes.
FOR FURTHER INFORMATION CONTACT: Margaret McCabe-Janicki, Center for
Devices and Radiological Health, Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 66, rm. 1535, Silver Spring, MD 20993-0002,
301-796-7029, or FDA Advisory Committee Information Line, 1-800-741-
8138 (301-443-0572 in the Washington, DC area), code 3014512519. Please
call the Information Line for up-to-date information on this meeting.
SUPPLEMENTARY INFORMATION: In the Federal Register of August 16, 2010,
FDA announced that a meeting of the General and Plastic Surgery Devices
Panel of the Medical Devices Advisory Committee would be held on
November 18, 2010. On page 49940, in the second column, in the Agenda
portion of the document, the first full paragraph is changed to read as
follows:
Agenda: On November 18, 2010, the committee will discuss, make
recommendations, and vote on information related to the premarket
approval application for MelaFind, sponsored by MELA Sciences.
MelaFind(R) is a non-invasive and objective multi-spectral computer
vision system designed to aid physicians in the detection of early
melanoma from among clinically atypical (those having one or more
clinical or historical characteristics of melanoma, such as asymmetry,
border irregularity, color variegation, diameter greater than 6
millimeters, evolving, patient concern, regression, and ``ugly
duckling'') cutaneous pigmented lesions that are non-ulcerated, not
bleeding, and less than 2.2 centimeters in diameter, when a physician
chooses to obtain additional information before making a final decision
to biopsy to rule out melanoma.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated: September 30, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2010-24983 Filed 10-4-10; 8:45 am]
BILLING CODE 4160-01-S
